RxDoctor Payments Data

Julia Philip-Kuli

Family Medicine · Chicago, ILNPI 1417262031

Payments from drug & device makers

$453in general payments, 2019–2025

Across 20 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$217
  • Boehringer Ingelheim$82
  • Sanofi Pasteur Inc.$37
  • GSK$32
  • Amarin Pharma, Inc.$26
  • E.r. Squibb & Sons, L.L.C.$18
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$44197%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$453 in reported general payments places this provider in the 60th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$145,345
Medicare patients
347
Services billed
1,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$129,769
MounjaroTirzepatide24$43,305
EliquisApixaban34$31,662
JardianceEmpagliflozin24$31,389
XareltoRivaroxaban11$17,085
JanuviaSitagliptin Phosphate15$14,464
Breo ElliptaFluticasone/Vilanterol26$10,287
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,031
GemtesaVibegron23$7,746
Triamterene11$7,201
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$4,661
Levothyroxine Sodium219$2,649
Rosuvastatin Calcium202$2,310
Metoprolol Succinate160$2,039
Atorvastatin Calcium227$2,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$217$129,76990 claims
PfizerEliquis$17$31,66234 claims
Boehringer IngelheimJardiance$82$31,38924 claims
GSKBreo Ellipta, Trelegy Ellipta$32$20,31840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →